Time to progression · men with metastatic, hormone‐sensitive prostate cancer
Abiraterone + ADT probably leads to lower time to disease progression measured at a median compared with ADT alone (moderate certainty).
1 finding from 1 review
Discontinued treatment due to adverse events measured at a median · men with metastatic, hormone‐sensitive prostate cancer
Abiraterone + ADT probably leads to higher discontinued treatment due to adverse events measured at a median compared with ADT alone (moderate certainty).
1 finding from 1 review
Urologic symptom scores · men with lower urinary tract symptoms suggesting benign prostatic hyperplasia
1 finding from 1 review
Quality of life · men with lower urinary tract symptoms suggesting benign prostatic hyperplasia
1 finding from 1 review
Major adverse events · men with lower urinary tract symptoms suggesting benign prostatic hyperplasia
It is very uncertain whether convective radiofrequency water vapour thermal therapy changes major adverse events compared with sham procedure (very low certainty).
1 finding from 1 review
Retreatment · men with lower urinary tract symptoms suggesting benign prostatic hyperplasia
It is very uncertain whether convective radiofrequency water vapour thermal therapy changes retreatment compared with sham procedure (very low certainty).
1 finding from 1 review
Erectile function · men with lower urinary tract symptoms suggesting benign prostatic hyperplasia
1 finding from 1 review
Ejaculatory function · men with lower urinary tract symptoms suggesting benign prostatic hyperplasia
1 finding from 1 review
Stone clearance assessed by imaging · adults with renal and ureteral stones undergoing shock wave lithotripsy
1 finding from 1 review
Auxiliary treatment · adults with renal and ureteral stones undergoing shock wave lithotripsy
1 finding from 1 review
Major adverse events · adults with renal and ureteral stones undergoing shock wave lithotripsy
1 finding from 1 review
Quality of life · adults with renal and ureteral stones undergoing shock wave lithotripsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Stone clearance time measured in days · adults with renal and ureteral stones undergoing shock wave lithotripsy
1 finding from 1 review
Urinary continence within 1 week after catheter removal MCID: 5% absolute difference · men (ages > 18 years) with clinically localized prostate cancer
Retzius‐sparing RALP probably leads to higher urinary continence within 1 week after catheter removal MCID: 5%… compared with standard RALP (moderate certainty).
1 finding from 1 review
Urinary continence 3 months after surgery MCID: 5% absolute difference · men (ages > 18 years) with clinically localized prostate cancer
Retzius‐sparing RALP may leads to higher urinary continence 3 months after surgery MCID: 5% absolute difference compared with standard RALP (low certainty).
1 finding from 1 review
Serious adverse events · men (ages > 18 years) with clinically localized prostate cancer
It is very uncertain whether retzius‐sparing RALP changes serious adverse events compared with standard RALP (very low certainty).
1 finding from 1 review
Urinary continence 12 months after surgery MCID: 5% absolute difference · men (ages > 18 years) with clinically localized prostate cancer
Retzius‐sparing RALP showed no clear difference in urinary continence 12 months after surgery MCID: 5% absolute… compared with standard RALP (moderate certainty).
1 finding from 1 review
Potency 12 months after surgery MCID: 5% absolute difference · men (ages > 18 years) with clinically localized prostate cancer
It is very uncertain whether retzius‐sparing RALP changes potency 12 months after surgery MCID: 5% absolute difference compared with standard RALP (very low certainty).
1 finding from 1 review
Positive surgical margins MCID: 5% absolute difference · men (ages > 18 years) with clinically localized prostate cancer
Retzius‐sparing RALP may leads to higher positive surgical margins MCID: 5% absolute difference compared with standard RALP (low certainty).
1 finding from 1 review
Biochemical recurrence‐free survival · men (ages > 18 years) with clinically localized prostate cancer
It is very uncertain whether retzius‐sparing RALP changes biochemical recurrence‐free survival compared with standard RALP (very low certainty).
1 finding from 1 review